A phase I/II trial of dabrafenib + trametinib + hydroxychloroquine in patients with BRAF-mutant melanoma demonstrated promising response rates in a treatment refractory patient population, but did not meet the pre-specified 1 year PFS rate of 60% [47]. This evidence concerns the gene BRAF and melanoma.